Preferred Label : CDK4/6 Inhibitor TQB3303;
NCIt definition : An orally bioavailable selective inhibitor of cyclin-dependent kinase (CDK) types
4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration,
CDK4/6 inhibitor TQB3303 selectively targets and inhibits CDK4 and CDK6, which inhibits
the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents
CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses
DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine
kinases that are upregulated in many tumor cell types and play a key role in the regulation
of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.;
Molecule name : TQB 3303; TQB-3303;
NCI Metathesaurus CUI : CL1413423;
Origin ID : C175968;
UMLS CUI : C5446893;
Semantic type(s)
- concept_is_in_subset
- has_target
